NCT06493370View on ClinicalTrials.gov

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2030

Conditions
Bladder Cancer
Interventions
DRUG

Intravenous ascorbic acid/vitamin C

A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles

Trial Locations (2)

52242

NOT_YET_RECRUITING

Holden Comprehensive Cancer Center - The University of Iowa, Iowa City

66160

RECRUITING

The University of Kansas Cancer Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER